Cue Biopharma (NASDAQ:CUE) Issues Earnings Results

Cue Biopharma (NASDAQ:CUE) released its earnings results on Monday. The company reported $0.01 EPS for the quarter, FiscalAI reports. The firm had revenue of $21.94 million during the quarter. Cue Biopharma had a negative return on equity of 271.67% and a negative net margin of 530.75%.

Cue Biopharma Price Performance

NASDAQ CUE traded up $0.03 during mid-day trading on Monday, hitting $0.31. The stock had a trading volume of 1,325,544 shares, compared to its average volume of 1,155,850. Cue Biopharma has a twelve month low of $0.23 and a twelve month high of $1.05. The stock has a market capitalization of $24.49 million, a price-to-earnings ratio of -0.68 and a beta of 1.52. The firm’s 50 day moving average is $0.32 and its 200 day moving average is $0.53. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.66 and a quick ratio of 1.66.

Institutional Investors Weigh In On Cue Biopharma

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Cue Biopharma by 730.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after purchasing an additional 73,000 shares during the period. Squarepoint Ops LLC acquired a new position in shares of Cue Biopharma in the third quarter valued at approximately $62,000. Boothbay Fund Management LLC purchased a new stake in Cue Biopharma during the 3rd quarter worth approximately $439,000. GC Wealth Management RIA LLC lifted its holdings in Cue Biopharma by 35.0% during the 4th quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company’s stock worth $1,415,000 after buying an additional 1,200,000 shares in the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc lifted its holdings in Cue Biopharma by 1,231.2% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after buying an additional 407,568 shares in the last quarter. Institutional investors and hedge funds own 35.04% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cue Biopharma in a research note on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cue Biopharma currently has a consensus rating of “Sell”.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.